Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
98.22
+0.54 (0.55%)
Sep 5, 2025, 12:21 PM - Market open
Illumina Revenue
Illumina had revenue of $1.06B in the quarter ending June 29, 2025, a decrease of -4.77%. This brings the company's revenue in the last twelve months to $4.28B, down -3.27% year-over-year. In the year 2024, Illumina had annual revenue of $4.37B, down -2.93%.
Revenue (ttm)
$4.28B
Revenue Growth
-3.27%
P/S Ratio
3.61
Revenue / Employee
$413,115
Employees
10,370
Market Cap
15.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 4.37B | -132.00M | -2.93% |
| Dec 31, 2023 | 4.50B | -80.00M | -1.75% |
| Jan 1, 2023 | 4.58B | 58.00M | 1.28% |
| Jan 2, 2022 | 4.53B | 1.29B | 39.73% |
| Jan 3, 2021 | 3.24B | -304.00M | -8.58% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ILMN News
- 2 days ago - Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development - PRNewsWire
- 8 days ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha
- 4 weeks ago - Illumina: The Stock Is Still Undervalued - Seeking Alpha
- 5 weeks ago - These Analysts Boost Their Forecasts On Illumina Following Upbeat Results - Benzinga
- 5 weeks ago - Illumina, Inc. (ILMN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025 - PRNewsWire
- 5 weeks ago - Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling - PRNewsWire
- 7 weeks ago - Illumina Stock: What Went Wrong And Why It's Best To Stay Away - Benzinga